COLL — Collegium Pharmaceutical Balance Sheet
0.000.00%
- $860.81m
- $1.55bn
- $631.45m
- 64
- 82
- 76
- 87
Annual balance sheet for Collegium Pharmaceutical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 174 | 186 | 174 | 311 | 163 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 83.3 | 106 | 183 | 180 | 229 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 278 | 316 | 420 | 538 | 482 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 27.4 | 27.1 | 26.4 | 22 | 20.2 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 644 | 692 | 1,174 | 1,143 | 1,664 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 239 | 280 | 434 | 458 | 510 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 458 | 489 | 979 | 948 | 1,435 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 186 | 203 | 195 | 195 | 229 |
Total Liabilities & Shareholders' Equity | 644 | 692 | 1,174 | 1,143 | 1,664 |
Total Common Shares Outstanding |